Antigen presentation by resting splenic B cells has been shown previously to induce T helper I cell (Thl) anergy. In contrast to expectations, it was found here that B cells treated with F(ab')2 goat anti-mouse immunoglobulin (IgM) for 24 or 48 h also presented antigen (Ag) to Thl cells in a manner that induced dramatic Ag-specific proliferative inactivation. The tolerogenicity of the anti-Ig-treated B cells was consistent with the observation that these B cells were only slightly more efficient than resting B cells in stimulating human gamma globulin (HGG)-induced proliferation of HGG-specific Thl cells in primary cultures. The activated B cells were, however, more efficient than resting B cells in stimulating a primary mixed leukocyte reaction, and exhibited increased expression of major histocompatibility complex class II molecules, RL388 Ag and transferrin receptor. In addition, unlike resting B cells, which expressed little detectable B7, antiIg-treated B cells expressed high levels of B7. The functional capacity of the B7 expressed on the activated B cells was demonstrated by the fact that the Ag-presenting capacity of these B cells was inhibited by the addition to culture of CTLA4Ig, a soluble receptor for B7. It is unlikely that the tolerogenicity of the activated B cells was due to an inability of the Thl cells to respond to B7 signals; the Thl clones used in the experiments, unlike the Th2 clones tested, expressed CD28, the ligand for B7. In addition, anti-CD28 monoclonal antibody inhibited the induction of Thl cell anergy when added to cultures of Thl cells and Ag-pulsed fixed antigen-presenting cells. Taken together, the results indicate that B cells, even when activated, do not satisfy the costimulatory requirements of the Thl cells used here, and therefore can present Ag in a tolerogenic fashion to Thl cells. The costimulator deficiency of activated B cells may reflect an inadequacy in the level of B7 expressed or a lack of some other molecule.
ntigen-specific inactivation of Thl cells can be induced in vitro by exposing the Thl cells to Ag presented by APCs that lack costimulatory molecules. Tolerogenic APCs often consist of spleen cells that have been pulsed with Ag and then chemically fixed (1, 2) . However, there is also evidence showing that nonfixed resting B cells are capable of presenting Ag to T cells in a tolerogenic fashion. It has been noted in several systems that lightly irradiated resting B cells are either ineffective or inferior APCs for the initiation of primary Thl responses to mitogens or antigens (3) (4) (5) (6) . Using Thl clones specific for human gamma globulin (HGG) 1, it was found that B cell inefficiency as APCs was associated with antigen-specific inactivation: Thl cells exposed to HGG and lightly irradiated splenic B cells in primary cultures were unable to proliferate to HGG and immunogenic APCs in secondary cultures (7) . In vivo, the role of B cells as tolerogenic APCs has been demonstrated in mice by using Fab fragments 1 Abbreviations used in this paper: CM, conditioned medium; FAPC, fixed antigen presenting cells; FCF, flow cytofluorimetric; FH, Ficoll-Hypaque; FI, fluorescein; HGG, human gamma globulin; IF, immunofluorescent; TfR, transferrin receptor. of rabbit anti-mouse IgD to induce tolerance specific for nonimmune rabbit Ig (8) . Tolerance to rabbit Ig was apparently dependent on antigen presentation by B cells, since intravenous injection of soluble Fab nonimmune rabbit Ig, which is not targeted to B cells, resulted in a lower degree of tolerance, especially at lower doses. It has also been demonstrated that injection of a population of spleen cells consisting primarily of small resting B cells induced hyporesponsiveness to MHC alloantigen (9) , and to the male-specific antigen H-Y in mice (10) . Presumably, the tolerogenicity of resting B cells is due to the fact that although resting B cells can present Ag in conjunction with MHC class II molecules, they lack the costimulatory molecules required to fully activate T cells.
Although the identity of the costimulator molecule whose absence may be associated with B cell tolerogenicity is not known, a good candidate for such a molecule is the B7/BB-1 antigen. B7 is not expressed on resting B cells, but is expressed on dendritic cells (11) which are particularly potent accessory cells for T cells (12) . The B7 molecule on APCs binds both CTLA-4, which is expressed on activated T cells (13) , and CD28, which is expressed on >80% of resting peripheral CD4 + T cells (14) . Ligation of CD28 initiates a 249 j. Exp. Med. 9 The Rockefeller University Press 9 0022-1007/94/01/0249/10 $2.00 Volume 179 January 1994 249-258 signal transduction pathway which appears to be separate from that initiated by TCtL ligation (for a review see reference 15) , and costimulates proliferation and IL-2 production by normal T cells in conjunction with antigens or mitogens (16, 17) . In terms of Thl cells specifically, it has been shown that anti-CD28 mAb costimulates proliferation of Thl cells to Agpulsed fixed spleen cells, and interferes with Thl cell inactivation in these cultures (18) . Thus, it appears that B7 ligation of CD28 on Thl cells has the capacity to costimulate Thl cell activation.
The potential for B cell-mediated ligation of CD28 on Thl cells is enhanced in activated B cells through the upregulation of B7. The increased B7 expression on activated B cells (19) (20) (21) appears to correlate with increases in certain aspects of B cell Ag presentation. Activated B cells have been shown to be more e~cient than resting B cells in promoting a MLR (22) , and in costimulating Ag-or mitogen-induced T cell proliferation (23) (24) (25) (26) . Aside from B7, a number of other B lineage-associated and restricted Ags (e.g., CDw40, CD23, and CD25) are upregulated on activated B cells (27) (28) (29) . Increased expression of MHC class II molecules is also observed on activated B cells (30) . Because of the increased expression of B7 and other accessory molecules and activation Ags on stimulated as compared to resting B cells, it seemed likely that activated B cells would, unlike resting B cells, present Ag to Thl cells in an immunogenic rather than a tolerogenic fashion. This study was conducted to test this point. In contrast to our expectations, activated B cells retained their ability to present Ag in a manner that led to Thl inactivation.
Materials and Methods
Animals. 4-5-wk-old male A/J mice were purchased from the National Cancer Institute (Bethesda, MD). Experiments were performed by using 8-12-wk-old mice. Female Lewis rats were purchased from The Jackson Laboratory (Bar Harbor, ME).
Antigens and Antibodies. Soluble HGG was purified from Cohn fraction II of human plasma by DEAE-cellulose chromatography as previously described (31) . Anti-Thy 1.2 mAb was purchased from New England Nuclear (Boston, MA). Hybridoma cells secreting 145-2Cll (hamster anti-mouse CD3e) were provided by Dr. J. A. Bluestone (University of Chicago, Chicago, IL) and the mAb was purified as described (32) . The sources and purification procedures for anti-RL388Ag mAb (RL388), anti-mouse transferrin receptor (TfR) mAb (R17.217), and polyclonal rat IgG were described previously (32) . PE-conjugated anti-B220 mAb and fluorescein (F1)-conjugated anti-Ia k mAb (specificity-2) were purchased from PharMingen (San Diego, CA). The CTLA4Ig fusion protein and the purified human mouse chimeric mAb L6 protein were kindly provided by Dr. Peter Linsley (Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA). Hamster anti-CD28 (mAb 37.51, IgG2a) mAb was kindly provided by Dr. James Allison (University of California at Berkeley, Berkeley, CA). Biotinylated anti-CD28 mAb was purchased from Caltag Laboratories (San Francisco, CA). Fl-goat F(ab')2 anti-human IgG (absorbed against mouse serum proteins) was purchased from Jackson ImmunoResearch (West Grove, PA).
Th Clones and Lines. The HGG-specific CD4 + Thl clones were developed, maintained, and characterized as previously described (2). The Con A conditioned medium (CM) used in maintaining the clones and as a source of IL-2 in the experiments described here, was prepared by collecting the supernatant from cultures of spleen cells from Lewis rats incubated at 106 cells/ml with 5/zg/ml Con A for 24 h.
Preparation of Fixed APCs. Splenocytes in RPMI-1640 medium (M. A. Bioproducts, Walkersville, MD) supplemented with 2 mM L-glutamine, 0.1 mM nonessential amino adds, 1 mM sodium pyruvate, 100 U/m1 penicillin, 100/zg/ml streptomycin, 5 x 10 -s M 2-ME, and 5% FCS (M. A. Bioproducts) were incubated at 2 x 107/ml in medium alone, or with I mg/ml HGG for 3 h at 37~ The spleen cells were then washed in RPMI, passed over a FicollHypaque (FH) gradient to remove the dead cells, and fixed by using a modification of a previously described method (2) . Briefly, the spleen cells were incubated in I ml of 0.15% paraformaldehyde in HBSS for 1 min at 37~ The reaction was stopped by adding 7 ml of cold 0.5% glycylglycine. The fixed APCs were washed three times in medium before use.
Primary Cultures for lndudng Thl Cell Unresponsiveness. Thl cells were harvested from culture 7-12 d after the last antigenic stimulation. They were passed over a FH gradient to remove old APCs, and incubated at 2.5 x 105 cells/ml in 0.2 ml medium consisting of i part Click's medium, I part supplemented RPMI-1640 medium, and 10% FCS. Also added to the primary cultures were untreated or activated B cells (5 x 106/ml) together with HGG. In some experiments, 5 x 106/ml HGG-pulsed fixed antigen presenting cells (FAPC) were added to the wells. The control cultures received B cells in the absence of HGG, or FAPC prepared in the absence of HGG. After incubation (48- 
Immunofluorescent Staining and Flow Cytofluorometric Analysis.
The formulation of staining medium and procedures for two-stage immunofluorescent (IF) staining were described previously (32) . The mAb and polyclonal IgG were conjugated with F1 or PE as described previously, and were ultracentrifuged to eliminate aggregates (32) . B cells from preincubation cultures were harvested at 36 h and viable B cells were isolated by FH density centrifugation and two-color IF stained for B220 versus membrane RL388 Ag, Ia K, TfR, and B7. Non-B220 § cells (T cells or macrophages) were excluded from analysis by gating on B220 + cells. Staining B7 was a two-step procedure involving an initial treatment with CTLA4Ig (5 #g/ml) or human mouse chimeric mAb L6 (5/~g/ml), followed by treatment with Fl-labeled goat F(ab')2 anti-human IgG in the presence of 5% normal mouse serum. Th cells or anti-CD3-activated spleen cells were one color-stained for B7 expression in a manner similar to that used for B cells. Th cells were also IF stained for CD28 using biotinylated anti-CD28 mAb and PE-streptavidin. The stained cells were examined by flow cytofluorometry using a FACS | IV flow cytometer (Becton Dickinson & Co., Mountain View, CA), and optical arrangements and machine settings for the FACS | IV were previously described in detail (32) .
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Tolerogenicity of Resting and Activated B Cells
For two-color analyses using FI reagents, F1 frequency distributions histograms obtained from PE-gated viable cells were generated as described (32) .
Preparation of Splenic B Cells. Splenic B cells were isolated by double passage of T cell-depleted spleen cells over Sephadex G-10 (Pharmacia, Uppsala, Sweden) columns as described (7). The resulting spleen cell population was examined by cytofluorometric (FCF) analysis periodically and found to consist of >95% B220 § cells. The B cells were incubated at 5 x 106/ml for 24 or 48 h in medium alone, or in the presence of F(ab')2 goat anti-mouse IgM (Jackson ImmunoResearch; 10 #g/ml) _+ 25/xg/ml LPS (Escherichia coli 0111:B4; Calbiochem-Novabiochem Corp., La Jolla, CA) or 4 ng/ml recombinant mouse IFN-y (Genentech, San Francisco, CA). After preincubation, the B cells were irradiated at 950 tad or treated with 50/~g/ml mitomycin C (Sigma Chemical Co., St. Louis, MO) for 45 min at 37~ before use in primary cultures.
Bioassays for Monitoring B Cell Ag Presentation.
To examine the ability of B cells to present HGG to the Thl cells, B cells were added (5 x 106/m1 unless otherwise specified) to 0.2-ml cultures of FH-purified Thl cells (2.5 x 10S/ml) in the absence or presence of HGG (500 #g/ml unless otherwise specified). Proliferation 
Results

Ag-presenting Capacity of Activatecl B Cells. This study to
examine the tolerogenicity of activated B cells was begun by determining whether activated B cells were in fact more efficient than resting B cells in presenting HGG to HGGspecific Thl cells. Resting splenic B cells were left untreated or treated with F(ab')2 goat anti-mouse IgM alone or in combination with LPS or IFN-3, for 24 h. At this time, the B cells were tested for their ability to serve as APCs in two different assays, i.e., ability to present HGG to HGG-specific Thl cells, and ability to present allo-specific Ag in a MLR. As can be seen in Fig. 1 , the most effective APCs in terms of presenting HGG to the Thl clones were untreated spleen cells. As shown previously (7) 
Ability of Activated B Cells to Present Ag in a Tolerogenic Fashion to Thl Cells.
Even though anti-Ig-treated B cells were not efficient stimulators of HGG-specific Thl cell proliferation, it seemed likely that the ability of these B cells to stimulate a MLR was due to expression of costimulatory molecules that would decrease, to at least some degree, the tolerogenicity of the activated B cells. To test this possibility, resting splenic B cells were incubated for 24 h in medium alone, in the presence of anti-Ig alone, or in combination with LPS. The B cells were then lightly irradiated (950 tad) and incubated in primary cultures with Thl cells in the presence or absence of HGG. After 3 d, the Thl cells from the primary cultures were isolated and reincubated in secondary cultures stimulated with HGG and irradiated spleen cells as APCs, or with IL-2-containing Con A CM. As shown previously, Thl cells from primary cultures containing HGG and resting B cells lost their ability to proliferate in Ag-stimulated secondary cultures (Fig. 2) . In contrast to our expectation, B cells treated with anti-Ig in the presence or absence of LPS also induced a dramatic decrease in the Ag-specific proliferative capacity of Thl cells. Thl ceils incubated in primary cultures containing either resting or activated B cells but no HGG proliferated normally in the HGG-stimulated secondary cultures. All groups of Thl cells proliferated in a similar fashion in IL-2-containing secondary cultures. Based on these results, it appears that incubation of B cells with anti-Ig for 24 h does not inhibit the ability of the B cells to present HGG in a tolerogenic fashion to Thl cells. B cell tolerogenicity was dose dependent. A summary of five experiments revealed that in the presence of 500/zg/ml HGG, Thl inactivation decreased from 78 to 66 to 49% when resting B cells were titrated from 2.5 • 106/ml to 5 • 105/ml to 105/ml, respectively, in primary cultures of Thl cells. Experiments were also conducted in which Thl cells were exposed in primary cultures to 500/zg/ml HGG and unseparated spleen cells in concentrations of 5 • 106/ml, 106/ml, or 2 • 10S/ml. The Thl cells were washed after 3 d, rested for 3 d, and reincubated in Ag-stimulated secondary cultures. The unseparated spleen cells were unable to inactivate Thl cells by >16% at any concentration tested.
Antigenicit 7 and Tolerogenicity of B Cells Stimulated for 48
Rather than 24 h. It has been reported that although the Ag-presenting capacity of B cells is enhanced after 24 h in the presence of B cell stimulants, this enhanced capacity does not become resistant to chemical fixation or moderate doses of irradiation (3,000 rad) until after 48 h in the presence of the stimulants (32, 33) . Therefore, it seemed possible that the unaltered tolerogenicity of B cells stimulated for 24 h with anti-Ig was due to the fact that some aspect of B cell Ag presentation only becomes evident after 48 h in culture. This possibility was rendered unlikely when it was found that B cells treated with anti-Ig for 48 h were still inefficient stimulators of HGG-specific proliferation by Thl cells even though they were now as efficient as unseparated spleen cells in stimulating a MLR (Fig. 3) . The inability of anti-Ig to stimulate B cells capable of stimulating HGG-specific proliferation of Thl cells was not enhanced if LPS was used in conjunction with anti-Ig to pretreat the B cells. In addition, experiments to test the tolerogenicity orb cells stimulated with anti-Ig for 48 h showed that these B cells did not lose their ability to present HGG in a tolerogenic fashion to Thl cells (Fig. 4) . The anti-Ig-treated B cells were tolerogenic whether they were lightly irradiated or mitomycin C treated before use as APCs. Thus, activation orb cells for 48 rather than 24 h did not alter the tolerogenicity of the B cells.
Expression of Accessory Molecules on Activated B Cells. Experiments were conducted to determine the extent to which anti-Ig treatment enhanced B cell expression of accessory molecules. Splenic B cells were incubated in medium alone, or in the presence of antiolg. After 36 h, the B cells were subjected to fluorescent staining and FCF analysis. The B220 § B cells were examined for their expression of B7 molecules, as well as other Ags (e.g., MHC class II molecules, RL388, and TfR) which can be used as markers for B cell activation.
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Tolerogenicity of Resting and Activated B Cells For example, hyperexpression of Ia molecules is used as a marker for early B cell activation (30) , whereas upregulation of RL388 and TfR are observed during early and late G1 phase, respectively (32) . Untreated resting B cells expressed moderate levels of MHC class II molecules, low levels of RL388 Ag and TfR, and no detectable B7 (Fig. 5) . B cells treated with anti-Ig exhibited a large increase in their expression of Ia and RL388, and a definite shift in TfR expression. Most Expression of CD28 and B7 on HGG-specific Th Clones. The fact that activated B cells expressing high levels orB7 retained the ability to present Ag in a tolerogenic fashion to Thl cells could be explained if Thl cells lacked CD28 and were therefore resistant to B7-mediated signaling. This possibility was examined and rejected after IF staining and FCF analysis of the Thl cells. Moderate to high levels of CD28 were expressed on all of the HGG-specific Thl clones examined (Fig. 6) . In contrast, the Th2 clones examined expressed no detectable CD28. CD28 expression was not enhanced when the Th2 cells were stimulated for 36 h with anti-CD3 mAb (data not shown). Since B7 has been shown to be expressed on human T cell clones (34), the expression orB7 on the HGGspecific murine Th clones was also examined. The levels of 253 Gilbert and Weigle B7 expressed by the different clones varied from moderate to low, and was not restricted to a particular Th cell subset. High levels of B7 were detected on spleen cells treated with anti-CD3 mAb. Untreated spleen cells expressed very low levels of B7 (data not shown).
Confirming Roles for B7 and CD28 in this System. Even though CD28 was expressed on the HGG-specific Thl cells, and B7 was expressed on the activated B cells used in these experiments, it seemed possible that for some reason in this system B7 and CD28 did not mediate the same effects observed in other systems. Accordingly, experiments were conducted to test the functional roles of B7 and CD28 in our system. This included an examination of whether the increased B7 expression observed on B cells treated with mitogens was associated with the increased capacity of the B cells to serve as APCs. The involvement of B7 in stimulating a MLR has been demonstrated by others (16, 35) who showed that blocking B7 interaction with CD28 by the use of B7 mAb or CTLA4Ig inhibited the MLR. In the experiment described here, CTLA4Ig was titrated into cultures containing resting or anti-Ig-treated splenic B cells from A/J mice (H-2") as stimulator cells together with C57B1/6 (H-2 b) splenic responder cells. As described in Fig. 3 , anti-Ig-treated B cells, unlike resting B cells, were efficient stimulators of a MLR (Fig. 7) . Addition of CTLA4Ig blocked, in a dose-dependent fashion, the ability of activated B cells to stimulate the MLR. The effect of CTLA4Ig on HGG-induced proliferation of the Thl cells was also examined. CTLA4Ig inhibited by 50% the modest ability of anti-Ig-treated B cells to promote HGGspecific proliferation (Fig. 8) . The APC capacity of unseparated spleen cells was also inhibited by CTLA4Ig. These results suggest that the activated B cells used in these experiments express functionally active B7 molecules, and that the HGGspecific Thl cells are responsive to B7-mediated signaling.
As confirmation that the HGG-specific Thl cells were responsive to B7-CD28 interactions, anti-CD28 mAb was tested for its ability to interfere with the ability of HGGpulsed fixed spleen cells to inactivate HGG-specific Thl cells. In three separate experiments, Thl cells were incubated in (uglml) Ability of CTLA4Ig to block MLR stimulated by activated in HGG-stimulated secondary cultures (Fig. 9) . The Agspecific inactivation induced by HGG-FAPC was prevented if anti-CD28 mAb was also present in the primary cultures. Similarly, anti-CD28 mAb inhibited Thl cell anergy induced by resting or anti-Ig-treated B cells. Taken together, these results show that at least some of the functional effects of CD28 and B7 described in other systems can be demonstrated in the present system.
CTLA41g in cultures
Discussion
It seemed likely that the previously documented ability of resting B cells to present Ag to Thl cells in a tolerogenic rather than stimulatory fashion (7) was due to a lack of B cell costimulatory molecules, notably B7. However, in contrast to expectations, treatments that were shown to enhance certain aspects of B cell Ag presentation, as well as B cell expression of accessory molecules including B7, were found here to have no effect on B cell tolerogenicity. Similar to untreated resting B ceils, anti-Ig-activated B cells presented Ag to Thl cells in a manner that induced Ag-specific proliferative inactivation. There is evidence to suggest that a similar phenomenon can also occur in vivo. Fuchs and Matzinger (10) showed that LPS-treated B cells from male mice were similar to resting B cells in their capacity to induce H-Y-specific inactivation when injected into female mice. This inactivation, which was demonstrated as a decrease in cytotoxic T cell responses and prolonged skin graft survival, was not induced if dendritic cells rather than B cells were injected. In potential contrast to our findings, it was shown in another study (8) that although divalent F(ab')2 fragments of rabbit anti-mouse IgD did induce unresponsiveness to nonimmune rabbit Ig in mice, the F(ab')2 fragments were less effective than monovalent fragments in inducing this inactivation. The authors suggested that the F(ab')2 fragments of anti-mouse Ig activated the B ceils by crosslinking surface Ig, and thereby reduced the tolerogenicity of resting B cells. However, the authors could not rule out the perhaps more likely possibility that the divalent fragments formed complexes with circulating IgD that were then captured and presented by professional APCs rather than B cells. In other studies, it was reported that even resting B cells possessed more costimulatory capacity for Thl cells than described here (33) , and could interfere with Thl cell tolerance induction when added to cultures of Thl ceils in the presence of peptide and fixed spleen cells (36) . The apparent disparity between these findings and our and others' results showing that resting B cells are poor costimulators for Thl cells (3, 7) , could be explained if certain Thl clones have fewer requirements for costimulatory activity. Along these lines, it was shown subsequently that the Thl clone A.E7, which was featured in both studies describing efficient B cell APC activity for Thl cells, differed from other Thl clones tested in that the A.E7 cells could bypass costimulator requirements and proliferate to immobilized anti-CD3 in the absence of accessory cells (37) . Therefore, the results obtained using the A. (35) . Whereas it has not been reported that CTLA4Ig binds to Fcgs on murine APCs, the possibility exists that CTLA4Ig blocks HGGspecific Ag presentation by inhibiting FcR-mediated uptake of HGG by APCs rather than by blocking B7 expression on APCs. Such a mechanism is, however, unlikely, and would not account for CTLA4Ig-mediated inhibition of a MLR. Thus, the results suggest that the levels of B7 expressed on the anti-Ig-stimulated B cells used in these experiments were functionally effective. It should be mentioned that even though anti-Ig treatment of B cells can stimulate expression of accessory molecules and DNA synthesis by these cells (32, 38) , it can also make the B cells refractory to further stimulation (39) . The anti-Ig-treated B cells used here were not tested for their subsequent proliferative capacity. However, even if the B cells were ultimately unresponsive, the results show that B cells that express B7, and are at least partially activated, can tolerize Thl cells.
The tolerogenicity of activated B cells cannot be attributed to the fact that the Thl cells used in this study were incapable of CD28-mediated signaling. All the Thl cells used in the experiments were found to express CD28. The association of CD28 expression with Thl clones fits in with the previous observation that mitogen-stimulated human CD28 + T cells make only those lymphokines produced by Thl cells (40) . The functional competence of the CD28 expressed by the Thl cells in this study was demonstrated when anti-CD28 mAb was shown to inhibit tolerance induction in HGG-specific Thl cells exposed to Ag-pulsed fixed APCs or Ag-presenting B cells. This finding is similar to that of Harding et al. (18) who showed that anti-CD28 mAb inhibited T cell inactivation when added to cultures of Thl cells specific for )x repressor protein and Ag-pulsed fixed APCs.
Taken together, the results presented here suggest that the Thl clones used in this study can be activated through CD28.
Although the HGG-specific Thl cells appear to have functionally active receptors for B7, upregulation of B7 expression on anti-Ig-treated B cells was not sufficient to alter the tolerogenicity of these B cells for Thl cells. This observation was somewhat surprising in view of the reported correlation between B7 expression and APC costimulatory activity. The ability of B cell tumor lines to stimulate a MLR has been shown to correlate with expression of B7 (41), and B7-transfected CHO cells, unlike untranslated cells, can costimulate a MLR, as well as mitogen-induced and Ag-specific T cell proliferation (42) . In addition, blocking B7-mediated signaling appears to inhibit APC immunogenicity and enhance APC tolerogenicity. For example, it has been shown that CTLA4Ig treatment induced long-term tolerance to human pancreatic islet cells in mice (43) , and caused T cell hyporesponsiveness to alloantigens in a human mixed leukocyte culture (44) .
Although the studies described above argue convincingly that blocking B7-mediated signaling inhibits the costimulatory activity of B7-expressing APCs, and enables these APCs to present Ag in a tolerogenic fashion to CD4 + T cells, the results of our study suggest that the reverse may not necessarily be true. It appears that increasing the B7 expression on tolerogenic APCs does not necessarily enable these APCs to present Ag in an immunogenic fashion to CD4 + T cells. Similar to our fndings using activated B cells, Freedman et al., (45) found that IFN-y treatment did not enhance the costimulatory capacity of the monocytes, even though it significantly enhanced B7 expression on monocytes. The authors proposed that the contrast between the costimulatory activity of B7-expressing monocytes and the costimulatory capacity of B7-transfected cells was linked to a quantitative difference in B7 expression. It has been reported that CD28 can induce two different levels of costimulation, one that is mediated by a pathway independent of the TCR and requires minimal CD28 receptor oligomerization, and one that requires a high degree of receptor crosslinking and delivers a more potent primary signal to the T cells (for review see reference 15). If B7 is present on the APCs in sufficient quantities (e.g., on B7-transfected APCs) to induce extensive CD28 crosslinking, this costimulatory molecule may be all that is required for Thl cell activation. On the other hand, it appears that under more physiological conditions, the level of B7 expression on activated B cells is not sufficient to fully costimulate Ag-specific proliferation of the Ag-specific Thl cells. Presentation of Ag to Ag-specific Thl cells may have more stringent requirements for costimulatory signals than other bioassays such as a primary MLR. Primary MLRs are often, as is the case in this study, performed in the presence of responder adherent cells which may provide accessory cell signals that amplify or even costimulate the signals provided by the alloantigen-bearing B cells. In addition, both Thl and Th2 CD4 § T cells, which have been shown to have different costimulator requirements (3), may participate in the MLR responder population.
The results from this study can be explained if Thl cell activation requires a certain cumulative level of costimulatory signals in addition to TCR ligation. This level of costimulatory activity may not be attainable on B cells. Two possible exceptions must be mentioned. First, Thl cells which for some reason have less stringent costimulator requirements than the Thl cells used here, may be stimulated by B cell APCs. Second, it is possible that unlike the activating regimes used in this study, certain B cell stimulatory treatments (e.g., interaction with Ag-activated Th2 cells) may induce more potent B cell costimulators, and turn B cells into efficient APCs for Thl cells. Bearing in mind these two possible caveats, it is possible to propose a model in which physiological levels of B7 on APCs are required but not sufficient for Ag-induced Thl cell activation. This would mean that blocking B7 would inhibit Thl cell activation and thus lead to tolerance induction, hut that expression of B7 at physiological levels, in the absence of other costimulatory signal(s), would not lead to complete Thl cell activation. Thl cell activation may require an additional, non-B7 costimulator signal, such as has been implicated in Thl stimulation by brain microvessel smooth muscle cells/pericytes (46) .
The role of B7 in stimulating Th2 activation is unclear. The Th2 cells tested in this study did not express CD28, eliminating this means of B7-mediated signaling. However, it is possible that these Th2 cells have lost CD28 expression as a result of long-term tissue culture. Alternatively, these Th2 cells may express the other ligand for B7, CTLA4, and are therefore still susceptible to B7-mediated signaling. It is also possible that Th2 cells, which can be activated to produce IL-4 by TCR crosslinking alone (47), may not require signaling from B7 and/or other putative costimulatory molecules. A lack of costimulatory requirements by Th2 cells would explain why resting B cells, which can crosslink the TCR, but appear to lack costimulator molecules, are efficient APCs for Ag-induced Th2 cell but not Thl cell proliferation (3, 7) .
